Wedbush set a $79.00 price target on Aimmune Therapeutics (NASDAQ:AIMT) in a research note released on Thursday, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently commented on AIMT. Cantor Fitzgerald reiterated a buy rating and issued a $27.00 price target on shares of Spero Therapeutics in a research note on Thursday, May 9th. Credit Suisse Group decreased their price target on Athene from $67.00 to $57.00 and set an outperform rating for the company in a research note on Tuesday, May 21st. ValuEngine raised Zillow Group from a hold rating to a buy rating in a report on Thursday. BidaskClub raised Zillow Group from a buy rating to a strong-buy rating in a report on Tuesday, July 2nd. Finally, Zacks Investment Research raised DLH from a sell rating to a hold rating in a report on Tuesday, July 9th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $41.43.

Aimmune Therapeutics stock opened at $19.00 on Thursday. The company has a 50-day simple moving average of $20.17. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.65 and a quick ratio of 7.65. Aimmune Therapeutics has a one year low of $16.95 and a one year high of $36.12.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.07. As a group, equities analysts predict that Aimmune Therapeutics will post -3.77 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. Sanders Morris Harris LLC purchased a new position in Aimmune Therapeutics during the second quarter worth approximately $5,436,000. FMR LLC increased its stake in Aimmune Therapeutics by 30.3% during the first quarter. FMR LLC now owns 2,734,583 shares of the biotechnology company’s stock worth $61,117,000 after acquiring an additional 635,362 shares during the last quarter. Marshall Wace North America L.P. acquired a new stake in Aimmune Therapeutics during the first quarter worth $32,000. Knott David M increased its stake in Aimmune Therapeutics by 4.2% during the first quarter. Knott David M now owns 55,056 shares of the biotechnology company’s stock worth $1,231,000 after acquiring an additional 2,199 shares during the last quarter. Finally, Botty Investors LLC acquired a new stake in Aimmune Therapeutics during the first quarter worth $2,505,000. 76.12% of the stock is currently owned by institutional investors and hedge funds.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Read More: Total Return

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.